The global angina pectoris drugs market size was valued at USD 11.14 billion in 2025 and is expected to reach USD 17.09 billion by 2033, at a CAGR of 5.50% during the forecast period

The market growth is largely fueled by the rising prevalence of cardiovascular diseases and increasing incidence of angina pectoris, driven by aging populations, sedentary lifestyles, and growing risk factors such as hypertension, diabetes, and obesity

Furthermore, continuous advancements in anti-anginal therapies, expanding adoption of combination drug regimens, and improved access to cardiovascular care across both developed and emerging healthcare systems are supporting market expansion and strengthening treatment uptake in clinical practice